Bloomberg
Jack Ma's Ant Group Explores ChatGPT-Style Services. Challenges Baidu with Investment in AI
- Alibaba Group Holding Limited's (NYSE:BABA) fintech affiliate Ant Group Co is developing large-language model technology to power ChatGPT-style services.
- The Jack Ma-backed affiliate's "Zhen Yi" project involves a dedicated unit and will deploy in-house research.
- Ant invested nearly 20.5 billion yuan ($2.8 billion) in R&D in 2023, doubling the company's annual spending on such efforts versus 2019.
Uber Rival Bolt Taps AI Robots For Food Delivery
- Uber Technologies Inc (NYSE:UBER) rival Bolt Technology OU will begin using robots to deliver customers' food orders under a new partnership.
- In 2023, the deal with Starship Technologies, created by two Skype cofounders, will see "thousands" of robots handling Bolt Food orders across multiple countries.
- The financial terms of the deal remain undisclosed.
Â
Reuters
YouTube Takes on TikTok in South Korea, Preps Up For Shopping Channel Debut Amid Competition
- Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) YouTube looks to launch its first official shopping channel for live commerce in South Korea on June 30, marking its official shopping channel debut in any country.
- The new channel will start as a 90-day project and operate in Korean.Â
- Initially, it will provide a live-commerce platform to companies and plans to livestream shopping content from about 30 brands.
Cisco Launches Power-Efficient Networking Chips, Takes on Broadcom and Marvell in AI Arena
- Cisco Systems Inc(NASDAQ:CSCO) on Tuesday launched networking chips for AI supercomputers that would compete with offerings from Broadcom Inc (NASDAQ:AVGO) and Marvell Technology Inc (NASDAQ:MRVL).
- Five of the six major cloud providers are testing chips from its SiliconOne series.
- Cisco said the chips could execute AI and machine learning tasks with 40% fewer switches and less lag while being more power efficient.
Chinese Regulators Reprimand Starbucks And Shake Shack Over Privacy Breach
Â
Benzinga
Dollar Tree Targets Achieving $10+ EPS In 2026, Sees Future Cash Flow For Capital Allocation
FDA Approves New Class of Oral Medicines for Children with Type 2 Diabetes
- On Tuesday, the FDA approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children ten years and older with type 2 diabetes.Â
- These approvals provide a new class of medicines taken by mouth to treat pediatric type 2 diabetes.Â
- The FDA granted approvals of Jardiance and Synjardy to Boehringer Ingelheim.
Panasonic Energy, Mazda Discuss Battery Supply Partnership
Mastercard's Green Initiative: Introducing a Global Strategy for Payment Card Recycling
RTX Secures $1.15B Contract From US Air Force; Collins Aerospace Inks MRO Agreement With Envoy Air
Piaggio Unveils Vespa's Disney Mickey Mouse Edition: Tribute to Disney's 100th Anniversary
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
